LON:MXC Argent BioPharma (MXC) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Argent BioPharma Stock (LON:MXC) 30 days 90 days 365 days Advanced Chart Get Argent BioPharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume264 shsAverage Volume26,353 shsMarket Capitalization£9.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia. Read More Receive MXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MXC Stock News HeadlinesUS in vivo study shows Argent’s ArtemiC effective in viral inflammatory modelAugust 24, 2025 | msn.comRunners of the Week: Kaili, Magnetite Mines, Argent Biopharma, OctavaAugust 22, 2025 | msn.comINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.August 29 at 2:00 AM | Traders Agency (Ad)Argent BioPharma Expands with Strategic Acquisition of AusCann AssetsAugust 19, 2025 | msn.comArgent starts EU-GMP cannabinoid supply for drug resistant epilepsy at Slovenia’s largest hospitalJuly 8, 2025 | msn.comArgent and AusCann partner to accelerate cannabinoid pharma developmentApril 15, 2025 | msn.comArgent BioPharma Prepares for Major Capital RaisingJanuary 2, 2025 | tipranks.comArgent BioPharma to Delist From London Stock Exchange, Mulls U.S. ListingNovember 29, 2024 | marketwatch.comSee More Headlines MXC Stock Analysis - Frequently Asked Questions How do I buy shares of Argent BioPharma? Shares of MXC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Argent BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Argent BioPharma investors own include Rolls-Royce Holdings plc (RR), Argo Blockchain (ARB), AutoZone (AZO), BP (BP), Chaarat Gold (CGH), Diageo (DGE) and EQTEC (EQT). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPetroleum And Natural Gas Current SymbolLON:MXC CIKN/A Webmgcpharma.com.au Phone61-8-6555-2950FaxN/AEmployees5Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£17.02 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-58.96% Debt Debt-to-Equity Ratio1,436.12 Current Ratio0.75 Quick RatioN/A Sales & Book Value Annual Sales£1.32 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 4 per share Price / BookN/AMiscellaneous Outstanding Shares43,850,000Free FloatN/AMarket Cap£9.65 million OptionableNot Optionable Beta1.03 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (LON:MXC) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argent BioPharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Argent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.